Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Cyclocreatine-13C3

Cyclocreatine-13C3 is the 13C-labeled Cyclocreatine (HY-W017540) . Cyclocreatine, a creatine analogue, acts as a brain-penetrant and potent bioenergetic protective agent by providing high levels of ATP. Cyclocreatine can be phosphorylated and dephosphorylated by creatine kinases. Cyclocreatine suppresses creatine metabolism ameliorating the cognitive, autistic and epileptic phenotype in a mouse model of creatine transporter defciency. Cyclocreatine protects against ischemic injury and enhances cardiac recovery during early reperfusion in dogs and rats. Cyclocreatine decreases plaque-adjacent neuronal dystrophy in TREM2-deficient mice with amyloid-β pathology. Cyclocreatine is proming for research of ischemic heart disease, cardiovascular diseases, Alzheimer’s disease and other neurodegenerative diseases associated with microglial dysfunction, prostate cancer[1][2][3][4][5].

Product Specifications

UNSPSC

12352005

Target

ATP Synthase; Isotope-Labeled Compounds

Related Pathways

Membrane Transporter/Ion Channel; Others

Field of Research

Cancer; Metabolic Disease; Neurological Disease; Cardiovascular Disease

Smiles

N[13C]1=NCCN1[13CH2][13C](O)=O

Molecular Formula

C2 13C3H9N3O2

Molecular Weight

146.12

References & Citations

[1]Salwa A Elgebaly, et al. Cyclocreatine protects against ischemic injury and enhances cardiac recovery during early reperfusion. Expert Rev Cardiovasc Ther. 2019 Sep;17 (9) :683-697.|[2]Tyler K Ulland, et al. TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease. Cell. 2017 Aug 10;170 (4) :649-663.e13.|[3]Patel R, et al. Cyclocreatine Suppresses Creatine Metabolism and Impairs Prostate Cancer Progression[J]. Cancer Res. 2022 Jul 18;82 (14) :2565-2575.|[4]Patel R, et al. Cyclocreatine suppresses prostate tumorigenesis through dual effects on SAM and creatine metabolism[J]. bioRxiv, 2021: 2021.02. 26.432994.|[5]Cacciante F, et al. Cyclocreatine treatment ameliorates the cognitive, autistic and epileptic phenotype in a mouse model of Creatine Transporter Deficiency[J]. Sci Rep. 2020 Oct 27;10 (1) :18361.

Shipping Conditions

Room temperature

Scientific Category

Isotope-Labeled Compounds

Clinical Information

No Development Reported

More Discoveries

Explore Other Products

Browse additional items from our catalog

IP6K2 Polyclonal Antibody
MBS9244063-01 0.1 mL

IP6K2 Polyclonal Antibody

Sign In for Pricing
View Details
IP6K2 Polyclonal Antibody
MBS9244063-02 5x 0.1 mL

IP6K2 Polyclonal Antibody

Sign In for Pricing
View Details
CXCL11 (TAC, SCYB11, SCYB9B, C-X-C Motif Chemokine 11, Beta-R1, H174, Interferon gamma-inducible Protein 9, Interferon-inducible T-cell alpha Chemoattractant, Small-inducible Cytokine B11) (MaxLight 650)
125500-ML650 100 µL

CXCL11 (TAC, SCYB11, SCYB9B, C-X-C Motif Chemokine 11, Beta-R1, H174, Interferon gamma-inducible Protein 9, Interferon-inducible T-cell alpha Chemoattractant, Small-inducible Cytokine B11) (MaxLight 650)

Sign In for Pricing
View Details
(S) -4-Propyldihydrofuran-2 (3H) -One
RG-P181507-01 10 mg

(S) -4-Propyldihydrofuran-2 (3H) -One

Sign In for Pricing
View Details
(S) -4-Propyldihydrofuran-2 (3H) -One
RG-P181507-02 25 mg

(S) -4-Propyldihydrofuran-2 (3H) -One

Sign In for Pricing
View Details
(S) -4-Propyldihydrofuran-2 (3H) -One
RG-P181507-03 50 mg

(S) -4-Propyldihydrofuran-2 (3H) -One

Sign In for Pricing
View Details